Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Cash from Financing Activities (2021 - 2025)

Aligos Therapeutics (ALGS) has disclosed Cash from Financing Activities for 5 consecutive years, with $123000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities rose 26.8% year-over-year to $123000.0, compared with a TTM value of $101.6 million through Dec 2025, up 28529.58%, and an annual FY2025 reading of $101.6 million, up 28529.58% over the prior year.
  • Cash from Financing Activities was $123000.0 for Q4 2025 at Aligos Therapeutics, up from -$53000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $101.7 million in Q1 2025 and bottomed at -$177000.0 in Q2 2025.
  • Average Cash from Financing Activities over 5 years is $13.5 million, with a median of $89000.0 recorded in 2021.
  • The sharpest move saw Cash from Financing Activities tumbled 1800.0% in 2024, then skyrocketed 535584.21% in 2025.
  • Year by year, Cash from Financing Activities stood at $552000.0 in 2021, then plummeted by 78.08% to $121000.0 in 2022, then surged by 72574.38% to $87.9 million in 2023, then tumbled by 99.89% to $97000.0 in 2024, then increased by 26.8% to $123000.0 in 2025.
  • Business Quant data shows Cash from Financing Activities for ALGS at $123000.0 in Q4 2025, -$53000.0 in Q3 2025, and -$177000.0 in Q2 2025.